In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

And we also had important innovation highlights, which we'll talk about a bit more over the course of the call; Kisqali's FDA ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

The new Mercedes-Benz eEconic is a first of its kind all-electric tanker truck helping to reduce emissions at Airbus’ Donauwörth facility by pumping sustainable aviation fuel (SAF) into new ...

This update reflects Kisqali’s efficacy in both node-positive disease and ... patents & legal, executive appointments, commercial strategy and financial results. Daily roundup of key events in pharma ...

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization ...

EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast cancer. Kisqali showed a 25.1% reduced risk of cancer recurrence in Phase 3 NATALEE trial. The CHMP ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...